[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2447815T3 - Compuestos espiro sustituidos y su utilización para la preparación de medicamentos contra el dolor - Google Patents

Compuestos espiro sustituidos y su utilización para la preparación de medicamentos contra el dolor Download PDF

Info

Publication number
ES2447815T3
ES2447815T3 ES10012043.5T ES10012043T ES2447815T3 ES 2447815 T3 ES2447815 T3 ES 2447815T3 ES 10012043 T ES10012043 T ES 10012043T ES 2447815 T3 ES2447815 T3 ES 2447815T3
Authority
ES
Spain
Prior art keywords
aliphatic compound
gen
optionally substituted
cycloaliphatic group
diastereomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10012043.5T
Other languages
English (en)
Inventor
Hans Prof. Dr. Schick
Robert Dr. Frank
Melanie Dr. Reich
Ruth Dr. Jostock
Gregor Dr. Bahrenberg
Fritz Dr. Theil
Brigitta Dr. Henkel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Application granted granted Critical
Publication of ES2447815T3 publication Critical patent/ES2447815T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos espiro sustituidos de fórmula general I **Fórmula** donde m es 0, 1, 2, 3 o 4, n es 1, R1 representa un grupo -C(>=S)-NR8R9; o, cuando m es distinto de 0 y/o R5 es distinto de H, además un grupo -C(>=O)-NR6R7; R2 representa un grupo alifático lineal o ramificado, saturado o insaturado, no sustituido o al menos monosustituido, en caso dado incluyendo un heteroátomo como miembro de la cadena; donde los sustituyentes de los grupos alifáticos se pueden seleccionar independientemente de entre el grupo consistente en F, Cl, Br, I, -CN, -NO2, -OH, -SH y -NH2; un grupo cicloalifático saturado o insaturado, no sustituido o al menos monosustituido, en caso dado incluyendo un heteroátomo como miembro del anillo, en caso dado unido mediante un grupo alquileno, alquenileno o alquinileno, lineal o ramificado, no sustituido o al menos monosustituido, en caso dado incluyendo un heteroátomo como miembro de la cadena y/o condensado con un sistema de anillo mono- o poli-cíclico, no sustituido o al menos monosustituido; o un grupo arilo o heteroarilo no sustituido o al menos monosustituido, en caso dado unido mediante un grupo alquileno, alquenileno o alquinileno, lineal o ramificado, no sustituido o al menos monosustituido, en caso dado incluyendo un heteroátomo en la cadena, y/o condensado con un sistema de anillo mono- o poli-cíclico, no sustituido o al menos monosustituido.
ES10012043.5T 2005-05-19 2006-05-17 Compuestos espiro sustituidos y su utilización para la preparación de medicamentos contra el dolor Active ES2447815T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005023784 2005-05-19
DE102005023784A DE102005023784A1 (de) 2005-05-19 2005-05-19 Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln

Publications (1)

Publication Number Publication Date
ES2447815T3 true ES2447815T3 (es) 2014-03-13

Family

ID=36646208

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10012043.5T Active ES2447815T3 (es) 2005-05-19 2006-05-17 Compuestos espiro sustituidos y su utilización para la preparación de medicamentos contra el dolor
ES06742950T Active ES2370038T3 (es) 2005-05-19 2006-05-17 Compuestos espiro sustituidos y su uso para la preparación de medicamentos contra el dolor.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06742950T Active ES2370038T3 (es) 2005-05-19 2006-05-17 Compuestos espiro sustituidos y su uso para la preparación de medicamentos contra el dolor.

Country Status (13)

Country Link
US (1) US20080214807A1 (es)
EP (2) EP1893620B1 (es)
JP (1) JP5376941B2 (es)
AT (1) ATE524478T1 (es)
CA (1) CA2608385A1 (es)
CY (1) CY1112137T1 (es)
DE (1) DE102005023784A1 (es)
DK (1) DK1893620T3 (es)
ES (2) ES2447815T3 (es)
PL (2) PL1893620T3 (es)
PT (1) PT1893620E (es)
SI (1) SI1893620T1 (es)
WO (1) WO2006122769A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
JP5420408B2 (ja) * 2006-08-25 2014-02-19 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型のインヒビター
JP5451646B2 (ja) 2008-02-27 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8765735B2 (en) * 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
CN102753527B (zh) 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
BR112018014305B1 (pt) 2016-01-13 2023-10-17 Grünenthal GmbH Derivados de 3-((hetero-)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
EA034898B1 (ru) 2016-01-13 2020-04-03 Грюненталь Гмбх Производные 8-амино-2-оксо-1,3-диазаспиро[4,5]декана
TWI640514B (zh) 2016-01-13 2018-11-11 歌林達有限公司 ３－（羧甲基）－８－胺基－２－側氧基－１，３－二氮－螺－［４．５］－癸烷衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0888344A1 (en) * 1996-03-15 1999-01-07 The Du Pont Merck Pharmaceutical Company Spirocycle integrin inhibitors
AU6780398A (en) * 1997-03-28 1998-10-22 Du Pont Merck Pharmaceutical Company, The Heterocyclic integrin inhibitor prodrugs
WO1999058139A2 (en) * 1998-05-08 1999-11-18 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
DE10130020A1 (de) * 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
JP2005526137A (ja) * 2002-05-17 2005-09-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アミノテトラリン−誘動尿素のバニロイドｖｒ１受容体調節剤
EP1542692B1 (en) * 2002-05-22 2011-01-05 Amgen Inc. Aminopyrimidine derivatives for use as vanilloid receptor ligands for the treatment of pain
DE102004032567A1 (de) * 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine

Also Published As

Publication number Publication date
WO2006122769A3 (de) 2007-03-15
EP2292625B1 (de) 2013-12-25
WO2006122769A2 (de) 2006-11-23
EP1893620B1 (de) 2011-09-14
EP1893620A2 (de) 2008-03-05
PL1893620T3 (pl) 2012-02-29
CA2608385A1 (en) 2006-11-23
US20080214807A1 (en) 2008-09-04
DE102005023784A1 (de) 2006-11-30
EP2292625A1 (de) 2011-03-09
PL2292625T3 (pl) 2014-04-30
JP5376941B2 (ja) 2013-12-25
ATE524478T1 (de) 2011-09-15
CY1112137T1 (el) 2015-11-04
DK1893620T3 (da) 2012-01-16
SI1893620T1 (sl) 2012-04-30
ES2370038T3 (es) 2011-12-12
PT1893620E (pt) 2011-10-31
JP2008540592A (ja) 2008-11-20

Similar Documents

Publication Publication Date Title
ES2447815T3 (es) Compuestos espiro sustituidos y su utilización para la preparación de medicamentos contra el dolor
AU2011215704B2 (en) Secondary structure stabilized NMDA receptor modulators and uses thereof
CA2523261A1 (en) Fused pyrimidine derivatives with crf activity
WO2004014902A8 (en) Compounds having an activity at metabotropic glutamate receptors
SE9904508D0 (sv) New compounds
EA200400953A1 (ru) Замещённые пиридиноны в качестве модуляторов map-киназы p38
PT1599167E (pt) Derivados de benzimidazole e de imidazo-piridina, tendo uma afinidade para os receptores das melanocortinas e a sua utilização como medicamento
ATE326453T1 (de) Antithrombotische amide
MX2007007220A (es) Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos.
EA200400762A1 (ru) Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции
DE60103050D1 (de) Spiro[2.4]heptanaminocarbonsäure und ihre derivate
SI1910381T1 (sl) Substituirane spojine 1-oksa-3,8-diazaspiro(4,5)-dekan-2-on in njihova uporaba za pripravo zdravil
SE0102055D0 (sv) New Compounds
BRPI0517425A (pt) composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto
Wrobleski et al. Cyclobutane derivatives as potent NK1 selective antagonists
EA200500882A1 (ru) N-арилсульфонил-3-аминоалкоксииндолы
AR048973A1 (es) (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas
MXPA04005426A (es) Derivados de pirazol de anillos fuisionados.
MXPA05008186A (es) Derivados de quinoxalina saturados y su uso como ligandos receptores de glutamato metabotropico.
CA2490115A1 (en) Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
CY1110613T1 (el) Υποκατεστημενες θειαζολες και η χρησιμοποιηση τους για την παρασκευη φαρμακων
MXPA05011476A (es) Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2.
MXPA05011521A (es) Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo.
AR050956A1 (es) Derivados de bencimidazol; sintesis de los mismos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por ligandos del receptor cb1.
RU94032285A (ru) Цефалоспориновые соединения, способ их получения, фармацевтическая композиция